AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05098743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed medication list
Description: Patients will receive a printed out medication list from their electronic medical record.
Study NCT05760261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered.
Study NCT05760261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3882347
Description: GSK3882347 will be administered.
Study NCT06141473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frexalimab
Description: SAR441344 Solution for IV infusion
Study NCT06141473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Aubagio oral tablet
Study NCT06141473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusion
Description: Solution for IV infusion
Study NCT06141473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Oral tablet
Study NCT06141473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRI contrast-enhancing agents
Description: IV, as per respective label
Study NCT06141473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRI contrast-enhancing agents
Description: IV, as per respective label
Study NCT06141473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.
Study NCT06141473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholestyramine
Description: oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.
Study NCT06141473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Description: oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.
Study NCT06141473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Activated charcoal
Description: oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.
Study NCT05038566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pointdexter
Description: i-Digits partial hand prosthesis modified with the investigational pointdexter finger in place of the usual index finger.
Study NCT05597878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Given after surgery 5 mg every 6 hours as needed for severe pain.
Study NCT05597878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Given after surgery 1000 mg by mouth 4 times daily (every 6 hours)
Study NCT05597878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Given before and during surgery 1.5 mg/kg intravenously
Study NCT05597878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Given during surgery 15 mg or 30 mg intravenously 3 times daily (every 8 hours). After surgery 15 mg IV three times daily (every 8 hours).
Study NCT05597878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Given during surgery 1 mg intravenously 4 times daily (every 6 hours). After surgery 1000 mg by mouth four times daily (every 6 hours)
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIMS2_SF questionnaire
Description: At D0, M12 and M24. The Arthritis Impact Measurement Scales 2 Short Form (AIMS2-SF) is a specific tool to measure changes in global health, pain, mobility and social function in patients with arthritis. It was described in 1992 in patients with rheumatoid arthritis and osteoarthritis and include 26 items that are summarized in scales according to a predefined scoring system: mobility, physical activity (walking, bending, lifting), dexterity, household activity (managing money and medications, housekeeping), social activities, activities of daily living, pain, depression, and anxiety. The French translation has been validated and this questionnaires has been widely used in the rheumatology field to assess quality of life of patients with arthritis. Because HFE related arthropathy is very similar to osteoarthritis this questionnaire is ought to be adequate in this setting.
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WOMAC questionnaire
Description: At D0, M12 and M24. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a widely used questionnaires specifically assessing lower limb (hips and knee) osteoarthritis. It measures five items for pain, two for stiffness and 17 for functional limitation and had been translated in French.
Study NCT04873622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health
Description: RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
Study NCT05909293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venclexta 100 MG Oral Tablet
Description: When there is a deficiency of neutrophils, G-CSF treatment may be necessary. The treatment is continued until the absolute neutrophil count (ANC) reaches either >0.5×109/L and remains at that level for 3 consecutive days, or >2×109/L. The purpose of G-CSF therapy in this context is to stimulate the production of neutrophils and restore their levels to a sufficient and stable range. This helps to strengthen the immune system and reduce the risk of infections associated with low neutrophil counts.~When experiencing Grade 3-4 thrombocytopenia, subcutaneous injection of IL-11 can be administered as a treatment.~When symptoms of infection occur, aggressive antimicrobial therapy and other supportive treatments should be administered.~All blood products should undergo irradiation when transfused, and all blood products must be filtered before infusion.~If gastrointestinal adverse reactions occur, antiemetic medications can be administered to alleviate symptoms.
Study NCT06478823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stools donation
Description: Healthy volunteer donors included in the selection process to donate stool for the preparation of a TMF as part of research projects.~Donors will be followed from their selection until 6 months after their last valid stool donation.
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WOMAC questionnaire
Description: At D0, M12 and M24. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a widely used questionnaires specifically assessing lower limb (hips and knee) osteoarthritis. It measures five items for pain, two for stiffness and 17 for functional limitation and had been translated in French.
Study NCT05491343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MedroxyPROGESTERone Injection [Depo-Provera]
Description: The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
Study NCT05491343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Other
Description: Follow up using US
Study NCT06550830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sinovac PCV24 formulation 1
Description: One dose of Sinovac PCV24 formulation 1(0.5mL)
Study NCT06550830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sinovac PCV24 formulation 2
Description: One dose of Sinovac PCV24 formulation 2(0.5mL)
Study NCT06550830 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13®
Description: One dose of PCV13 manufactured by Pfizer
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQ-5D-5L questionnaire
Description: At D0, M12 and M24. The EQ-5D is a standardized instrument which evaluates the generic quality of life (http://www.euroqol.org/). It is a preference-based health-related quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The answers given to EQ-5D permit to find 243 health states that can be converted into utility score anchored at 0 for death and 1 for perfect health. EQ-5D is an instrument developed in Europe, widely used in cost-utility analysis. It has been validated in a representative sample of French population.
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L questionnaire
Description: At D0, M12 and M24. The EQ-5D is a standardized instrument which evaluates the generic quality of life (http://www.euroqol.org/). It is a preference-based health-related quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The answers given to EQ-5D permit to find 243 health states that can be converted into utility score anchored at 0 for death and 1 for perfect health. EQ-5D is an instrument developed in Europe, widely used in cost-utility analysis. It has been validated in a representative sample of French population.
Study NCT04779593 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample Complete blood count
Description: Blood Sample Complete blood count at D0, M6, M12, M18 and M24/end follow-up visit
Study NCT05625425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LabyrinthVR software
Description: Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, highly engaging regimen of wayfinding in novel urban and village neighborhoods.
Study NCT05625425 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Games software
Description: Commercially-available, narrative computer games marketed as cognitively enriching. Can be tablet-based or wireless VR headset-based.
Study NCT05625425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labyrinth Tablet software
Description: Tablet computer playing Labyrinth spatial wayfinding game in 2.5D
Study NCT05625425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labyrinth VR wireless
Description: Wireless head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, engaging regimen of wayfinding in novel urban and village neighborhoods.
Study NCT04632641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES
Description: The Perclose ProGlide Suture-Mediated Closure System (SMC) will be used to close the vein access site(s) at the completion of the large-bore procedure in order to achieve hemostasis.
Study NCT04632641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Figure 8 Suture - LARGE-BORE PROCEDURES
Description: A figure 8 suture will be done as a closure strategy in order to achieve hemostasis in large-bore procedures.
Study NCT05432115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracyclin
Description: Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid
Study NCT05432115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracyclin
Description: Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid
Study NCT06780761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation training
Description: The author further demonstrated taking body temperature, heart rate and its characteristics, respiratory rate and saturation, blood pressure and pain assessment in line with previously created cases on the NOELLE® Maternal Birthing Simulator with Advanced Resuscitation Neonatal M-W45111 to the students deployed in the intervention group. Furthermore the students were allowed to work individually on the infant simulator, their questions were answered and feedback was given to them. Students were also offered free time to work on the infant simulator. One week after the training, before proceeding with the clinical practice, the students were individually assessed on measuring the vital signs by 2 different observers and were administered the post-tests.
Study NCT06780761 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical training
Description: Before proceeding with the clinical practice, the students deployed in the control group were trained on how to measure the five vital signs, which tools to use and why, and normal and abnormal vital sign values by demonstration and explaining on a pediatric nursing manikin. Then, volunteering students were given the opportunity to develop their vital sign measurement skills on a pediatric nursing manikin and feedback was provided to them. One week after the training, all students were individually assessed on measuring the vital signs by 2 different independent observers on the simulator neonatal used in the intervention group and they were administered the post-tests.
Study NCT06781203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally delivered CBTI (eCBTI)
Description: Based on the existing consensus concerning non-pharmacological treatment of insomnia, Hvil® includes the following treatment components: sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy. Intervention duration is approximately six to nine weeks.
Study NCT06781515 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral and BM blood sample
Description: Peripheral and BM blood samples will be analyzed with the ddPCR method
Study NCT04149288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-polyphenol olive oil
Description: High-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
Study NCT04149288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-polyphenol olive oil
Description: Low-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
Study NCT05709535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]-PSMA-1007
Description: \[18F\]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of \[18F\]PSMA-1007 for PET scan.
Study NCT05336266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days
Study NCT05660980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once daily CAB tablet + RPV tablet
Description: Tablet
Study NCT05660980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting CAB injectable + long acting RPV injectable
Description: Injectable
Study NCT05586191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation at home
Description: Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects.
Study NCT05586191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action Observation therapy at hospital
Description: Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects.
Study NCT06565260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in exercise program
Study NCT06565260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear an activity tracker
Study NCT06565260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Participate in nutrition program
Study NCT06565260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06565260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05226845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prescribed exercise
Description: the therapist chooses the five exercises to do
Study NCT05226845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chosen exercise
Description: the patient chooses the five exercises to perform among fifteen possibilities
Study NCT05675917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MacuTest platform
Description: The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform.~The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient.~The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet).
Study NCT04638829 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Avatrombopag Oral Tablet
Description: Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information
Study NCT06554587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)
Description: Measurement of the plasma concentration of ST6GAL1, GCNT1 and GALNT7 biomarkers in patients suspected of having prostate cancer or on active surveillance
Study NCT04946305 — intervention group
Intervention type: OTHER
Intervention: Lutathera
Description: Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT04848896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CORI Robotics
Description: Total knee arthroplasty (TKA) treated with CORI Robotics System.
Study NCT04848896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Procedure
Description: Total knee arthroplasty (TKA) treated with conventional approach with conventional manual instrumentation.
Study NCT05464758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated cold exposure
Description: 8 consecutive days of exposure to 8°C air for 120 minutes each day
Study NCT04892420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia.
Study NCT04892420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The patients receive 20 ml plain bupivacaine(0.5)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
Study NCT04892420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: The patients receive 20 ml plain bupivacaine(0.5)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
Study NCT04892420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.